These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 33568438)
41. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Mavaddat N; Antoniou AC; Mooij TM; Hooning MJ; Heemskerk-Gerritsen BA; ; Noguès C; Gauthier-Villars M; Caron O; Gesta P; Pujol P; Lortholary A; ; Barrowdale D; Frost D; Evans DG; Izatt L; Adlard J; Eeles R; Brewer C; Tischkowitz M; Henderson A; Cook J; Eccles D; ; van Engelen K; Mourits MJE; Ausems MGEM; Koppert LB; Hopper JL; John EM; Chung WK; Andrulis IL; Daly MB; Buys SS; ; Benitez J; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Van Leeuwen FE; Arver B; Olsson H; Schmutzler RK; Engel C; Kast K; Phillips KA; Terry MB; Milne RL; Goldgar DE; Rookus MA; Andrieu N; Easton DF; ; ; Breast Cancer Res; 2020 Jan; 22(1):8. PubMed ID: 31948486 [TBL] [Abstract][Full Text] [Related]
42. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250 [TBL] [Abstract][Full Text] [Related]
43. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK. Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205 [TBL] [Abstract][Full Text] [Related]
44. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Ladd MK; Peshkin BN; Senter L; Baldinger S; Isaacs C; Segal H; Philip S; Phillips C; Shane K; Martin A; Weinstein V; Pilarski R; Jeter J; Sweet K; Hatten B; Wurtmann EJ; Phippen S; Bro D; Schwartz MD Transl Behav Med; 2020 May; 10(2):337-346. PubMed ID: 30418620 [TBL] [Abstract][Full Text] [Related]
45. Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation. Narod SA; Butler R; Bobrowski D; Akbari MR; Curling D; Lunn J; Ho C; Panahi S; Llacuachaqui M; Donenberg T; Hurley J Mol Genet Genomic Med; 2018 Mar; 6(2):301-304. PubMed ID: 29266833 [TBL] [Abstract][Full Text] [Related]
46. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ; J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320 [TBL] [Abstract][Full Text] [Related]
47. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828 [TBL] [Abstract][Full Text] [Related]
48. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice? Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307 [TBL] [Abstract][Full Text] [Related]
49. Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan. Nomura H; Abe A; Fusegi A; Yoshimitsu T; Misaka S; Murakami A; Matsumoto T; Tsumura S; Kanno M; Aoki Y; Netsu S; Omi M; Tanigawa T; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Habano E; Arakawa H; Kaneko K; Ueki A; Haruyama Y; Inari H; Ueno T Sci Rep; 2023 Jan; 13(1):1018. PubMed ID: 36658289 [TBL] [Abstract][Full Text] [Related]
50. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers. Stroot IAS; Bart J; Hollema H; Jalving M; Wagner MM; Yigit R; van Doorn HC; de Hullu JA; Gaarenstroom KN; van Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez García EB; Ausems MGEM; Boere IA; van Hest LP; Duijkers FAM; van Asperen CJ; Schmidt MK; Wevers MR; Ruijs MWG; Devilee P; Collée JM; Hebon Investigators ; de Bock GH; Mourits MJE Gynecol Oncol; 2024 Aug; 187():198-203. PubMed ID: 38795508 [TBL] [Abstract][Full Text] [Related]
51. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487 [TBL] [Abstract][Full Text] [Related]
52. Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer. Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA; Fam Cancer; 2017 Oct; 16(4):461-469. PubMed ID: 28285341 [TBL] [Abstract][Full Text] [Related]
53. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
54. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer. Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642 [TBL] [Abstract][Full Text] [Related]
55. Combined Bilateral Salpingo-oophorectomy and Cesarean Delivery in BRCA1/2 Alteration Carriers : A Case Series. Barker VE; Vlachodimitropoulou E; O'Brien P; Iskaros J; Rosenthal AN Obstet Gynecol; 2023 Dec; 142(6):1500-1503. PubMed ID: 37917945 [TBL] [Abstract][Full Text] [Related]
56. Management of hereditary breast and ovarian cancer. Yamauchi H; Takei J Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095 [TBL] [Abstract][Full Text] [Related]
57. Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. Manchanda R; Menon U Int J Gynecol Cancer; 2018 Jan; 28(1):34-42. PubMed ID: 29252925 [TBL] [Abstract][Full Text] [Related]
58. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P; Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637 [TBL] [Abstract][Full Text] [Related]
59. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
60. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]